Chiara Russo Recent News
Importance Of Phase 1 Trials
Cantor Raises Price Target For Paratek Pharma, Sees 82% Upside
Cantor Doesn't Think BioDelivery Sciences Should Be Cutting To Grow, Downgrades Stock To Hold
Cantor Initiates Heron Therapeutics With Buy Rating, $41 Price Target
Proxy Battle: What's Happening Between Starboard And DepoMed?
DepoMed's Latest Acquisition: Too Good To Be True?
Analyst Sees Success For Tonix Pharmaceuticals Holdings Corp.